Latest Genelex Corporation Stories
New team includes experts in patient care, medical technology, reimbursement and pharmacology focused on enabling genetics-based prescribing at the point of care. Seatte,
SEATTLE, Aug. 26 /PRNewswire/ -- The New York State Department of Health has licensed Genelex Corporation's DNA Drug Sensitivity Tests for use by doctors in the state.
SEATTLE, Wash. and LEXINGTON, Mass., June 8 /PRNewswire/ -- The first-ever comprehensive personalized prescribing services company has been formed with the merger of Seattle-based Genelex Corporation and Lexington, Massachusetts-based Mental Health Connections, Inc.
SEATTLE, Oct. 1 /PRNewswire/ -- One hundred eighty thousand women will be diagnosed with breast cancer this year. Eighty thousand will start taking the drug tamoxifen to prevent the recurrence of their ER (estrogen receptor) positive breast cancers.
SEATTLE, Oct. 30 /PRNewswire/ -- Nearly one third of breast cancer patients prescribed tamoxifen currently fail treatment.